|Bid||85.35 x 800|
|Ask||90.60 x 800|
|Day's Range||88.68 - 90.13|
|52 Week Range||74.09 - 94.26|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||25.86|
|Forward Dividend & Yield||3.33 (4.24%)|
|Ex-Dividend Date||Mar 08, 2022|
|1y Target Est||100.75|
Novartis (VTX:NOVN) has had a great run on the share market with its stock up by a significant 5.6% over the last...
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and serious complement-mediated blood disorder New data evaluating the superiority of first-line (1L) Kisqali® plus endocrine therapy vs. combination chemotherapy in pre-menopausal patients with HR+/HER2- metastatic breast cancer with aggressive disease, including patients with visceral disease New analysis fr